Pay in 4 interest-free payments of $5.83 Learn more
Ships within 48 hours · Estimated delivery Sep 8 - Sep 13
This is a preview of subscription content, access via your institution Access options Access Nature and 54 other Nature Portfolio journals Get Nature+, our best-value online-access subscription 27,99 / 30 days cancel any time Subscribe to this journal Receive 12 print issues and online access 192,54 per year only 16,05 per issue Buy this article Purchase on SpringerLink Instant access to the full article PDF
Each peptide vial is supplied as a high-purity lyophilised powder and manufactured under controlled laboratory conditions to ensure stability, purity, and consistency for scientific research applications
Discussion Significant weight reduction ability of semaglutide has been demonstrated in various phase-3 clinical trials, for which recently semaglutide became the first long-acting GLP-1 receptor agonist to be approved by the United States Food and Drug Administration for management of obesity
130 (7), 833841.e3
